Mar. 10 at 1:04 PM
$IVVD The appointment of Dr. Michael Mina as Chief Medical Officer (CMO) on March 5, 2026, has been viewed as a positive strategic catalyst by the market. Analysts suggest his background in infectious disease and public communication will strengthen the company's clinical execution and market education efforts.
Consensus Rating: Wall Street maintains a "Strong Buy" consensus for IVVD.
Price Targets: Analysts have set an average price target of
$8.75, with some reaching as high as
$10.00, suggesting significant potential upside.
$IBB $XBI $BIB $SPY